Abstracts tagged "proteomics"

Abstract Number: 1514 • ACR Convergence 2025
Serum Antigenome Profiling Reveals Diagnostic Models for Systemic Lupus Erythematosus
Yan Wang¹, Lulu Cao², Mengze Xu³, Jian Lu³, Jing He¹, Fanlei Hu⁴ and Zhanguo Li⁵, ¹Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China, Beijing, China (People's Republic), ²Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China, Beijing, ³State Key Laboratory of Protein and Plant Gene Research, Center for Bioinformatics, School of Life Sciences, Peking University, Beijing, China., Beijing, Beijing, China (People's Republic), ⁴Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China (People's Republic), ⁵Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China, Beijing, Beijing, China (People's Republic)
Background/Purpose: Systemic lupus erythematosus (SLE) exhibits profound clinical and pathogenic heterogeneity, complicating diagnosis and treatment. Identifying subtype-specific biomarkers might intrinsically link to organ involvement.Methods: Patients…
Abstract Number: 0094 • ACR Convergence 2025
Distinct immune-molecular signatures modulated ex vivo by JAK and TNF predict Rheumatoid Arthritis therapy outcomes in patients naïve to biologic and targeted synthetic DMARDs
Sagrario Corrales¹, Laura muñoz-Barrera¹, Rafaela Ortega-Castro², Elena Moreno-Caño³, Jerusalén Calvo⁴, Concepción Aranda-Valera⁴, Lourdes Ladehesa⁵, Pilar Font⁶, Ismael Sanchez-Pareja¹, M Carmen Abalos-Aguilera⁷, Desiree Ruiz-Vilchez⁸, Christian Merlo⁹, MARIA ANGELES AGUIRRE ZAMORANO¹, Tomás Cerdó¹, Nuria Barbarroja¹⁰, Marta Alarcon-Riquelme¹¹, Alejandro Escudero Contreras⁴, Carlos Pérez Sánchez¹² and Chary López pedrera¹³, ¹Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, ²Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, ³IMIBIC-Reina Sofia Hospital-University of Cordoba, Cordoba, Spain, Córdoba, Spain, ⁴IMIBIC / Reina Sofia Hospital / University of Cordoba, Córdoba, Spain, ⁵IMIBIC-Reina Sofia Hospital-University of Cordoba, Cordoba, Spain, Cordoba, Spain, ⁶Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, SpainBiomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain, ⁷Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, ⁸Department of Rheumatology, Reina Sofía University Hospital / Maimonides Institute for Biomedical Research of Córdoba (IMIBIC) / Department of Medical and Surgical Sciences, Faculty of Medicine, University of Córdoba, Spain, Cordoba, Spain, ⁹Rheumatology Service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/University of Cordoba/ Reina Sofia University Hospital, Córdoba, Spain, Cordoba, Spain, ¹⁰Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain, ¹¹Fundación Progreso y Salud, Andalusian Government, Granada, Spain, ¹²Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/ CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain, ¹³Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain
Background/Purpose: Despite advances in rheumatoid arthritis (RA) treatment, 20–40% of patients do not respond to biologic or targeted synthetic DMARDs (b/tsDMARDs). Understanding each drug’s molecular…
Abstract Number: 1515 • ACR Convergence 2025
Machine Learning–Defined Subtypes of Systemic Lupus Erythematosus Identify Distinct Immunologic and Molecular Signatures
Yuke Hou¹, Bo Wei², Jingyuan Liang³, Yujia Zhai⁴, Yan Wang⁵, Haihong Yao¹ and Zhanguo Li⁶, ¹Peking University People’s Hospital, Beijing, Beijing, China (People's Republic), ²Zhongshan Hospital Xiamen University, Xiamen, Fujian, China (People's Republic), ³North China University Of Science And Technology Affiliated Hospital, Tianjin, Tianjin, China (People's Republic), ⁴Bayannur City Hospital, Bayannur, Nei Mongol, China (People's Republic), ⁵Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China, Beijing, China (People's Republic), ⁶Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China, Beijing, Beijing, China (People's Republic)
Background/Purpose: To refine clinical subtypes of systemic lupus erythematosus (SLE) using unsupervised machine learning, and to elucidate the molecular basis of disease heterogeneity through integrated…
Abstract Number: 0112 • ACR Convergence 2025
Proteome-wide Mendelian Randomization Identifies Therapeutic Targets in Psoriatic Arthritis
Quan Li¹ and Proton Rahman², ¹University of Toronto, Toronto, Canada, ²Division of Rheumatology, Craig L. Dobbin Genetics Research Centre, Discipline of Medicine, Memorial University of Newfoundland, St. John's, Canada
Background/Purpose: While numerous proteins have been linked to psoriatic arthritis (PsA), the causal nature of these associations remains unconfirmed. This study aims to employ a…
Abstract Number: 1728 • ACR Convergence 2025
Longitudinal Proteomic Signatures for Prediction of Immune-Related Adverse Events during Immune Checkpoint Inhibitors therapy: A Machine Learning-Guided Prospective Biomarker Discovery Study
Jiana Chen¹, Jiaqi Xu¹, Ziyue Zhou², Xu Jiang¹ and Huaxia Yang¹, ¹Department of Rheumatology and Clinical Immunology, National Clinical Research Center for Dermatologic and Immunologic Diseases, the Ministry of Education Key Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, ¹⁰⁰⁷³⁰, Beijing, China, Beijing, China (People's Republic), ²peiking meidical, beijing
Background/Purpose: Immune checkpoint inhibitors (ICIs), while revolutionary in cancer treatment, may induce severe or even fatal immune-related adverse event (irAE). The mechanisms underlying irAE development…
Abstract Number: 0276 • ACR Convergence 2025
Plasma Proteomic Profiling Identifies Inflammatory Proteins and Pathways Associated With Non-idiopathic and Idiopathic Retroperitoneal Fibrosis
Thomas Pelowitz, Benjamin Hur, Kenneth Warrington, Jaeyun Sung and Matthew Koster, Mayo Clinic, Rochester, MN
Background/Purpose: Retroperitoneal fibrosis (RPF) is a rare fibroinflammatory disease of the retroperitoneum that can lead to obstructive uropathy and other life-threatening complications. While RPF can…
Abstract Number: 1798 • ACR Convergence 2025
Proteomic Profiling of Chondrogenic Gene Therapy in Human MSCs Reveals Distinct Regenerative Pathways for Articular Cartilage Repair
Patricia Quaranta¹, Jagadeesh K Venkatesan², Valentina Calamia³, Patricia Fernández-Puente⁴, francisco J Blanco⁵, Magali Cucchiarini² and Cristina Ruiz-Romero⁶, ¹Instituto de Investigacion Biomedica de A Coruna (INIBIC), coruna, Spain, ²Center of Experimental Orthopaedics, Saarland University and Saarland University Medical Center, Homburg, Germany, ³INIBIC, A Coruña, Spain, ⁴Instituto de Investigacion Biomedica de A Coruna (INIBIC), coruña, Spain, ⁵INIBIC-University of A Coruña, A Coruña, Galicia, Spain, ⁶Department of Rheumatology, Rheumatology Research Group (GIR) Biomedical Re-search Institute (INIBIC),, A Coruña, Spain
Background/Purpose: Rheumatic diseases are characterized by pain and a progressive loss of joint function. Classical treatments alleviate pain symptoms but fail to fully repair sites…
Abstract Number: 0297 • ACR Convergence 2025
Longitudinal Serum Proteomic Profiles – A Step Closer to Personalized Monitoring in Dermatomyositis
Natasha Le Blanc¹, Marie Hudson¹, Ana Cristina Gonzalez Sanchez², Lina Marcela Diaz Gallo² and Valerie Leclair³, ¹McGill University, Montréal, QC, Canada, ²Karolinska Institutet, Stockholm, Sweden, ³McGill University, Montréal, Canada
Background/Purpose: Dermatomyositis (DM) is a multisystemic immune mediated disease presenting with heterogeneous clinical features. Disease monitoring in DM relies in part on biomarkers of muscle…
Abstract Number: 1809 • ACR Convergence 2025
Mass Spectrometry-Based N-Terminomics Uncovers Proteolytic Signatures and Pathways in Juvenile Idiopathic Arthritis Synovial Fluid
Andrew Zeft¹, Sirada Panupattanapong², Laura Nedorezov³, Sumit Bhutada³ and Suneel Apte³, ¹Cleveland Clinic, Cleveland, OH, ²Cleveland Clinic Foundation, Cleveland, OH, ³Cleveland Clinic, Cleveland
Background/Purpose: Juvenile idiopathic arthritis (JIA) is a chronic disease marked by persistent synovial inflammation, often leading to structural joint damage. While numerous proteases produced by…
Abstract Number: 0506 • ACR Convergence 2025
Discovery-based Identification of Non-canonical Autoantibody Specificities in Ro Seronegative Sjögren’s Disease Using High-content Human Proteome Arrays
Songyuan Yao¹, Christina Lawrence¹, Hope Christakos², Charmaine Lopez-Davis¹, Bhuwan Khatri¹, Tommi C. Taylor¹, Astrid Rasmussen¹, Kiely Grundahl², R Hal Scofield¹, Blake M. Warner³, Judith James¹, Joel Guthridge¹, Christopher J. Lessard¹ and A. Darise Farris¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, Oklahoma City, ³National Institutes of Health, Bethesda, MD
Background/Purpose: Clinical tests for Sjögren’s disease (SjD) often overlook Ro-seronegative (RoNeg) cases, leading to delayed or missed diagnoses. Identifying additional serum autoantibodies could improve diagnostic…
Abstract Number: 1850 • ACR Convergence 2025
First American SLE patients demonstrate enhanced lipid metabolism and B cell activation by high-content proteomic analyses
Rufei Lu¹, Tayte Stephens², Carla Guthridge¹, Miles Smith¹, Joseph Kheir¹, Cristina Arriens¹, Joan Merrill³, Marci Beel⁴, Susan Macwana¹, Wade DeJager⁵, Nicholas Domingez¹, Teresa Aberle¹, Joel Guthridge¹ and Judith James¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²University of Oklahoma Health Science Center, Oklahoma City, OK, ³Oklahoma Medical Research Foundation, Oklahoma City ⁷³¹⁰⁴, OK, ⁴Oklahoma Medical Research Foun, Oklahoma City, OK, ⁵Oklahoma Medical Research Foundation, Oklahoma City
Background/Purpose: Systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) are autoimmune diseases with overlapping yet distinct immunopathologies. Proteomic profiling of soluble plasma factors can reveal…
Abstract Number: 0526 • ACR Convergence 2025
Identification of Urine Proteomic Biomarkers Associated with Ankylosing Spondylitis
Chang-Nam Son¹, Dong-Ki Jang², So-Hye Nam³, Yoon-Jeong Oh⁴, Sungsin Jo⁵, Jong-Seo Kim⁶ and Tae-Hwan Kim⁷, ¹UIJEONGBU EULJI MEDICAL CENTER, EULJI UNIVERSITY, UIJEONGBU, Republic of Korea, ²School of Biological Sciences, Seoul National University, Seoul, Republic of Korea, ³Division of Rheumatology, Department of Internal Medicine, School of Medicine, Keimyung University, Daegu, Republic of Korea, ⁴Uijeongbu Eulji Medical Center, Eulji University School of Medicine, Uijeongbu, Republic of Korea, ⁵Department of Biology, Soonchunhyang University, Asan,, Republic of Korea, ⁶School of Biological Sciences, Seoul National University, Seoul, ⁷Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea
Background/Purpose: Currently available diagnostic tests for inflammatory arthritis lack sufficient sensitivity and specificity, often requiring the integration of clinical manifestations with physician expertise for accurate…
Abstract Number: 1851 • ACR Convergence 2025
Endotype Discovery in Systemic Lupus Erythematosus Using Multi-Omic Approaches: Toward Precision Insights into Cardiovascular and Renal Damage
Chary López pedrera¹, Laurel Woodridge², Sagrario Corrales³, Juan Rafael Muñoz-Castañeda⁴, Ana Isabel Torralbo⁴, Anisur Rahman⁵, Filipa Farinha², Rafaela Ortega-Castro⁶, Pedro Seguí-Azpilcueta⁷, Ismael Sanchez-Pareja³, Laura muñoz-Barrera³, Christian Merlo-Ruiz⁸, Desiree Ruiz-Vilchez⁹, M Carmen Abalos-Aguilera⁸, Pilar Font¹⁰, Nuria Barbarroja¹¹, Marta Alarcon-Riquelme¹², Alejandro Escudero Contreras¹³, MARIA ANGELES AGUIRRE ZAMORANO³, Carlos Pérez Sánchez¹⁴, Elizabeth C Jury⁵ and Tomás Cerdó³, ¹Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain, ²Centre for Rheumatology Research, Division of Medicine, University College London, London, United Kingdom, ³Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, ⁴IMIBIC/Hospital Reina Sofía/University of Córdoba, Córdoba, Spain, ⁵University College London, London, United Kingdom, ⁶Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, ⁷Radiology Service, Reina Sofia Hospital/Maimonides Institute for Research in Biomedicine of Cordoba/University of Cordoba, Spain, Córdoba, United Kingdom, ⁸Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, ⁹Department of Rheumatology, Reina Sofía University Hospital / Maimonides Institute for Biomedical Research of Córdoba (IMIBIC) / Department of Medical and Surgical Sciences, Faculty of Medicine, University of Córdoba, Spain, Cordoba, Spain, ¹⁰Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, SpainBiomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain, ¹¹Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain, ¹²Fundación Progreso y Salud, Andalusian Government, Granada, Spain, ¹³IMIBIC / Reina Sofia Hospital / University of Cordoba, Córdoba, Spain, ¹⁴Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/ CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain
Background/Purpose: Systemic lupus erythematosus (SLE) is a multifaceted autoimmune disorder characterized by marked clinical variability, which complicates both diagnosis and treatment. Among its most severe…
Abstract Number: 0023 • ACR Convergence 2025
Longitudinal Proteomic Effects of Hydroxychloroquine in Individuals at Risk of Lupus: Differential Signatures in Progressors and Non-Progressors
Benjamin Jones¹, Miles Smith², Rufei Lu², Carla Guthridge², Susan Macwana², Wade DeJager³, Nancy Olsen⁴, Catriona Wagner⁵, Judith James², David Karp⁶ and Joel Guthridge², ¹Oklahoma State University, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, Oklahoma city, OK, ³Oklahoma Medical Research Foundation, Oklahoma City, ⁴Penn State University/Milton S Hershey, Hershey, PA, ⁵Oklahoma Medical Research Foundation, Santa Cruz, CA, ⁶UT Southwestern Medical Center, Dallas, TX
Background/Purpose: Hydroxychloroquine (HCQ) is routinely prescribed for treatment of systemic lupus erythematosus (SLE) due to its efficacy at decreasing disease activity/SLE flares and strong benefit:risk…
Abstract Number: 0799 • ACR Convergence 2025
Citrullination of neutrophil serine proteases enhances proteolytic activity, stability and autoantigenicity in Rheumatoid Arthritis
Mario Navarrete Lagos, Ramiza Zaman, Jun Kim, Jeba Atkia Maisha, Hani El-Gabalawy and Liam O'Neil, University of Manitoba, Winnipeg, MB, Canada
Background/Purpose: In Rheumatoid Arthritis (RA), autoantibodies develop against endogenous proteins containing the amino acid citrulline, which results from a post-translational modification of arginine catalyzed by…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].